In association with
Introduction
The classification of the PTEN hamartoma tumor syndromes (PHTS) was developed as a means of unifying the disparate disorders associated with germline mutations in the tumor suppressor gene PTEN (phosphatase and tensin homolog, deleted on chromosome 10).
1,2 PTEN encodes a dual phosphatase protein that negatively regulates the PI3K/Akt/mTOR pathway. Somatic loss of PTEN function through mutation, deletion, or methylation has been described in various sporadic human cancers, including those of the brain, bladder, breast, prostate, colon, lung, and endometrium, 3 and is thus under intense investigation by cancer researchers.
The PHTS are a spectrum of syndromes with variable clinical manifestations characterized by aberrant growth and associated with germline PTEN mutations. Hamartomas are a histologically distinct subtype of benign tumors in which cells maintain normal differentiation but are disorganized with respect to architecture. Cowden syndrome (CS) is the prototypic syndrome, characterized by mucocutaneous lesions, benign hamartomas, macrocephaly, and increased predisposition to breast, thyroid, and endometrial carcinoma. Lhermitte -Duclos (LD), a variant of CS, is characterized by dysplastic gangliocytomas of the cerebellum, which can lead to hydrocephalus, ataxia, and seizures.
After the discovery of the PTEN gene and the fact that CS is caused by germline mutations of PTEN, it became apparent that CS is allelic to other seemingly unrelated clinical syndromes. Bannayan -Riley -Ruvalcaba syndrome (BRRS), characterized by the developmental delay, macrocephaly, lipomas, hemangiomas, and speckled penis in males, is associated with PTEN mutations in approximately 60% of cases. Proteus syndrome has also been associated with germline PTEN mutations, although this is controversial. The clinical management of PHTS patients has historically focused on genetic counseling and screening. Indeed, patients with PHTS, particularly those with CS, should undergo early and frequent surveillance for susceptible malignancies. No medical therapies currently exist for PHTS patients. Because loss of PTEN increases activation of the PI3K/Akt/mTOR pathway, and inhibitors of this pathway are being developed as anticancer agents, these drugs might have therapeutic efficacy in patients with PHTS, which will be discussed further in this review.
PTEN biology
The PTEN gene (also known as MMAC1 for mutated in multiple advanced cancers, or TEP1 for TGF-b regulated and epithelial cell-enriched phosphatase) spans nine exons and is located on chromosome 10q22 -23. The gene encodes a 403 amino-acid protein, which acts as a dualspecificity phosphatase that dephosporylates lipids and proteins. PTEN exerts its lipid phosphatase activity by dephosphorylating the 3 0 -phosphoinositide products of PI3K, causing conversion of phosphatidylinositol (3, 4, 5) trisphosphate to phosphatidylinositol (4, 5) bisphosphate and conversion of phosphatidylinositol (3, 4) bisphosphate to phosphatidylinositol (4) phosphate. Reduction of 3 0 -phosphoinositides decreases activity of kinases downstream of PI3K such as phosphoinositide-dependent kinase 1, Akt, and mTOR, and is responsible for its tumor suppressor activity. Because of negative regulation of the Akt pathway, PTEN indirectly decreases phosphorylation of other substrates downstream of Akt such as p27, p21, GSK-3, Bad, ASK-1, as well as members of the forkhead transcription factor family (eg, AFX, FKHR, FKHRL1). Thus, a loss or reduction in PTEN activity leads to increased phosphorylation of many key cellular proteins, which in turn can affect processes such as cell cycle progression, metabolism, migration, apoptosis, transcription, and translation ( Figure 1) .
PTEN also has activities independent of its lipid phosphatase activity. As a protein phosphatase, PTEN dephosphorylates focal adhesion kinase, which can inhibit cell migration and cell spreading. 4 The protein phosphatase activity of PTEN can also regulate the mitogen-activated protein kinase pathway, thus regulating cell survival.
5,6
Shen et al 7 demonstrated that PTEN can promote chromosomal stability independent of its lipid phosphatase activity. 7 Targeted mutations of PTEN in its carboxyterminal domain, but not its phosphatase domain, caused centromere breakage and chromosomal translocations. Because mutations can occur throughout the PTEN gene, it is possible that chromosomal instability is characteristic of tumors derived from PHTS patients with mutations encoding the carboxy terminus of the protein.
In mouse models, complete inactivation of both copies of the PTEN gene before embryonic day 13.5 results in embryonic death because of aberrant differentiation and patterning of the germ layers. PTEN-null embryos exhibit poorly organized ectodermal and mesodermal layers, and overgrowth of the cephalic and caudal regions. 8, 9 Monoallelic inactivation, however, results in PTEN heterozygous knockout mice that are able to complete embryogenesis. Several features observed in PTEN heterozygous knockout mice are similar to those seen in PHTS syndromes. PTEN heterozygote mice develop neoplasms in many organs, including the liver, prostate, endometrium, GI tract, thymus, and thyroid. 10 Conversely, several groups have demonstrated that reconstitution of wild-type PTEN into a mutant PTEN background decreases activation of the PI3K/ Akt/mTOR pathway, alters cell cycle distribution, and/or induces apoptosis. 11 -13 These heterozygote knockout mice serve as potential animal models for PHTS, which will facilitate the development of novel therapies for patients with PHTS.
Overview of syndromes
Cowden syndrome Cowden syndrome was first described by Lloyd and Dennis 14 in 1963 in a case report of a patient with multiple hamartomas, unique mucocutaneous findings, fibrocystic breast disease, and abnormal neurologic findings. CS is an autosomal dominant disorder with age-related penetrance characterized by malignant and benign hamartomatous lesions affecting derivatives of all three germ cell layers.
Since the identification of the susceptibility gene PTEN, the estimated incidence of CS increased from 1 in 1 000 000 to 1 in 200 000 individuals. This most likely remains an underestimation, as CS is associated with a high degree of phenotypic variability and its hallmark features are under-recognized within the medical community. 15 In patients with CS, hamartomas can be found in virtually every organ, but most commonly in the skin and gastrointestinal (GI) tract. Mucocutaneous features, including trichilemmomas and papillomatous papules, are estimated to have a 99% penetrance in CS by the third decade of life. 1 Trichilemmomas are flesh-colored hamartomas of the outer sheath of the follicle that are typically near the hairline (Figure 2a ). Papillomatous papules are mucocutaneous lesions found on the face (Figure 2c ), oral mucosa, and acral surfaces (Figure 2b ). Gastrointestinal polyps in CS are typically asymptomatic, and can occur anywhere in the GI tract, with colonic polyps present in 60 -90% of patients. 16 The upper GI lesions are also relatively common (Figure 2d ), including glycogenic acanthosis, characterized by raised greywhite plaques in the distal esophagus, comprised of glycogen-filled squamous cells. 17 Despite the fact that the two most common sites for hamartomas in CS are the skin and GI tract, there is no definitive evidence that patients with CS are at increased risk to develop dermatologic or GI malignancies.
Benign thyroid lesions occur in up to 75% of patients with CS, including adenomas, hamartomas, multinodular goiter, and Hashimoto's thyroiditis. 16, 18 Up to half of women with CS are afflicted with benign breast disease, which can be extensive and bilateral. 19 In addition, The lifetime risk of thyroid cancer in both genders is estimated to approach 10%, as compared to less than 1% in the general population. The predominant thyroid cancer histology is follicular, although papillary thyroid cancers are observed as well. Endometrial cancer is more frequent in women with CS with an estimated risk of 5 -10% as compared to o2.5% in the general population, although this risk estimate in CS needs to be formally verified. 26 In addition to breast, thyroid, and endometrial cancers, other malignancies have anecdotally been reported to be increased with CS, including melanoma, renal cell carcinoma, and gliomas. In 1995, the International Cowden Consortium established a set of strict operational diagnostic criteria for CS on the basis of published data and expert opinions, which facilitated the identification of the susceptibility gene on chromosome 10q22 -23. The diagnostic criteria were revised in 2000 1 and in 2004, and are now updated annually by the US National Comprehensive Cancer Network (Table 2 ). In any patient who meets the pathognomonic criteria for CS, referral to a genetic counselor should be pursued and sequencing of PTEN should be considered. For patients who meet clinical criteria for CS but in whom sequencing of the coding region does not reveal a mutation in PTEN, further analysis of PTEN (eg, sequencing of the promoter region, assessment of PTEN protein levels) could be considered, but these approaches Figure 3 . With the expanding knowledge of the phenotypic manifestations of germline PTEN mutations, the diagnostic criteria will ultimately be refined to enable simpler diagnosis, thus increasing the likelihood of capturing patients with CS and ensuring that appropriate management is instituted. Before it was recognized as allelic to CS, BRRS was not considered to cause increased risk of malignancy. However, in a study of families with BRRS and CS overlap, a correlation between benign and malignant breast disease and germline PTEN mutation was observed, raising the possibility that BRRS is indeed associated with increased susceptibility to malignancy. 27 Given the genotypic and phenotypic similarities between BRRS and CS, and the possibility that these syndromes may represent a single disorder, BRRS patients should be counseled on adhering to screening guidelines recommended to CS patients (Table 3) .
Pathognomonic criteria for CS met (see Table 2 )
Risk assessment and counseling:
•Psychosocial assessment
•Risk counseling
•Education
•Discussion of genetic testing
•Informed consent PTEN mutation detected
•CS management (see Table 3) PTEN mutation not detected
•Routine medical care
•Consider additional methods to assess loss of PTEN expression
Pathognomonic criteria for CS not met
•Individualized recommendations according to personal and family history
•Consider screening for other genetic changes that contribute to early onset of cancer (for patients with breast, endometrial or thyroid cancer) Figure 3 Diagnostic algorithm for Cowden syndrome.
Proteus syndrome
Proteus syndrome (PS) was originally described by Cohen and Hayden in 1979, and was given its name by Wiedemann, after the Greek sea god known for his ability to change his shape. 44 Proteus syndrome is an extremely rare, highly variable disorder of post-natal mosaic growth dysregulation consisting of progressive, asymmetric, and disproportionate overgrowth. The clinical diagnosis of PS remains challenging and controversial, with misdiagnosis a frequent occurrence. 45, 46 PS is characterized by a sporadic, progressive, mosaic distribution of the following: cerebriform connective tissue nevi, epidermal nevi, asymmetric and disproportionate overgrowth involving disparate anatomical structures, dysregulated adipose deposits, ovarian cystadenomas, parotid adenomas, vascular malformations, lung cysts, and facial abnormalities. The underlying etiology of PS is unclear and its association with PHTS remains controversial. Zhou et al 47 were the first to report a putative association between PS and PHTS, in that two out of nine patients meeting established diagnostic criteria for PS possessed a germline PTEN mutation. Furthermore, in five individuals with Proteus-like features, who did not meet diagnostic criteria for PS, CS, or BRRS, three were found to have heterozygous germline PTEN mutation. A possible association between PS and heterozygous germline PTEN mutations was also corroborated by other investigators, 48 who found a germ- Given the controversy in associating PTEN mutation with PS, some have speculated that germline PTEN mutations can cause a distinct phenotype with features similar to PS. Happle 51, 52 recently distinguished between the thickened linear Cowden nevus, associated with a loss of the second copy of PTEN, and the pathognomonic linear Proteus nevus, which is typically flat. Caux et al 53 described
two patients from CS families with germline PTEN mutation who developed segmental overgrowth, vascular and lymphatic malformations, lipomatosis, and linear epidermal nevi reminiscent of PS. In one of these patients, a loss of the second PTEN allele in an atypical segmental lesion was reported. The authors propose the term 'SOLAMEN' syndrome (segmental overgrowth, lipomatosis, arteriovenous malformation and epidermal nevus) to account for these unusual patients. 53 A conclusive answer regarding PTEN mutations and PS awaits further study of the molecular basis underlying this syndrome.
Other clinical syndromes associated with loss of PTEN In addition to CS, LD, BRRS, and PS, there are other syndromes that may be associated with germline mutation or deletion of the PTEN gene. PTEN mutations have been described in patients with autism spectrum disorders (ASD) and macrocephaly. In an analysis of 88 patients with ASD and macrocephaly, a de novo missense PTEN mutation, D326N, was detected in a 5-year-old boy with autism, severe language delay, macrocephaly, and polydactyly of both feet. The authors conclude that screening for PTEN mutations should be considered in any patient with ASD and macrocephaly. 54 However, larger studies are needed to validate these findings. A germline PTEN mutation was also reported in an infant with features of VATER (vertebral 55 Germline PTEN mutations have been observed in patients with GI hamartoma syndromes not meeting criteria for CS or BRRS. In a study of 49 patients with unexplained GI hamartomas or hyperplastic polyposis, two patients were found to have germline PTEN mutations. One patient previously classified as Peutz -Jeghers syndrome had a PTEN deletion, and an infant with juvenile polyposis syndrome (JPS) had a hemizygous deletion encompassing both the PTEN and bone morphogenic protein receptor 1A (BMPR1A) genes on chromosome 10q23. 56 Similarly, Van Hattem et al 57 recently reported on a subset of patients with JPS with large genomic deletions of both BMPR1A and PTEN. With increased understanding of the spectrum of phenotypic features associated with germline PTEN mutations, which can vary widely from classic CS, it is possible that the spectrum of disorders within PHTS will expand. It is unknown whether patients who have germline PTEN mutations but phenotypically deviate from 'classic' CS should be managed according to the established guidelines (Table 3) , and should be included in trials investigating novel therapies for PHTS.
Clinical management

Screening
The most critical aspect in the management of patients with CS is heightened cancer surveillance, given that these patients are at increased risk to develop breast, thyroid, endometrial, and possibly other malignancies. Although it is not certain that patients with germline PTEN mutations who do not meet CS diagnostic criteria are at increased risk of developing cancers, Eng et al 1 have advocated that all patients with germline PTEN mutation undergo screening according to the NCCN guidelines (Table 3 ). Despite the logic that underlies this recommendation, it is unlikely that clinical trials will prove the efficacy of screening to reduce cancer mortality in PHTS patients. Nonetheless, screening that is performed as part of a clinical trial could support its wider application and provide opportunities to investigate prognostic features of benign and malignant tissues from these patients.
Surgical management
Patients with PHTS, particularly those with CS, are at increased risk ofr primary malignancy in certain organs, and similar to other familial cancer syndromes, are at increased risk of secondary malignancies as well. Therefore, prophylactic resection of susceptible organs may decrease the risk of potentially life-threatening malignancies. However, there is no data to support prophylactic surgery to decrease risk of malignancy or mortality, and likely these studies will never transpire because of the rarity of CS. Screening for breast cancer is particularly challenging in patients with CS because of the simultaneous presence of benign breast lesions such as fibrocystic changes and hamartomas. Annual mammogram and breast MRI beginning at age 30 -35 years as advocated by NCCN (Table 3) is likely to detect a high rate of early stage breast cancer. However, these modalities are also likely to yield a high degree of false positive data, which could lead to increased morbidity to CS patients because of unnecessary diagnostic procedures and heightened anxiety. Some women with CS may elect to undergo prophylactic bilateral mastectomy instead. In women who are BRCA1 and BRCA2 mutation carriers, which is associated with a 56 -87% lifetime breast cancer risk, studies have demonstrated a 90% risk reduction following prophylactic bilateral mastectomy. 58, 59 Women with CS, who carry a 30 -50% lifetime risk of breast cancer, may also derive benefit from prophylactic bilateral mastectomy. The 2007 NCCN guidelines for CS recommend discussion of options for risk reducing mastectomy on a case-by-case basis, and counseling regarding degree of protection, extent of cancer risk, and reconstruction options.
Total thyroidectomy is generally recommended in CS patients who develop thyroid cancer because of the risk of recurrent malignancy and the difficulty of repeat thyroid resections. In CS patients who develop benign thyroid lesions, a complete thyroidectomy is also recommended because of the increased risk of developing subsequent thyroid cancer and the increased morbidity of repeat biopsies to distinguish between benign nodules and malignancy. 20 As part of endometrial cancer screening, NCCN guidelines recommend annual blind endometrial biopsy for CS women who are pre-menopausal, and endometrial ultrasound for post-menopausal women. These guidelines make no specific recommendation regarding prophylactic hysterectomy. In some patients, such as post-menopausal women, the risk/benefit ratio may favor prophylactic hysterectomy. For patients with LD and dysplastic cerebellar gangliocytomas, surgical resection to alleviate symptoms related to hydrocephalus or mass effect is recommended; however, regrowth of LD lesions following resection has been reported. 37 Interventional treatment options for benign skin lesions related to PHTS include curettage, cryosurgery, and laser ablation.
Medical management
Standard medical therapies For women in the general population who are at increased risk of breast cancer, preventive hormonal agents such as tamoxifen or raloxifen can be considered in those who have at least a 1.6% 5-year risk. 60, 61 These agents could also be considered in women with CS; however, tamoxifen should be administered with extreme caution in women who have not undergone hysterectomy, given the potential for additive endometrial cancer risk. There are no proven chemopreventive strategies for thyroid and endometrial carcinoma, nor are there established medical therapies to reduce the growth or size of benign hamartomatous disease.
Experimental therapies A new strategy to control PHTS symptoms, prevent tumor growth, and/or treat established cancers is to test drugs that inhibit the PI3K/Akt/mTOR pathway in PHTS patients, given that loss of PTEN increases activation of the pathway in benign and malignant tissues of patients with PHTS and drives cellular proliferation, migration, and survival. An advantage of this strategy is that the accessibility of skin and GI hamartomas before and after therapy in PHTS patients would provide an opportunity to correlate changes in tumor growth and/or metabolism with changes in phosphorylation of pathway components such as Akt, S6K, S6, and 4E-BP1. The development of PI3K/Akt/mTOR inhibitors is an area of intense research in oncology, as this pathway promotes cellular survival and chemotherapeutic resistance in a variety of malignancies. Inhibition of proximal components of the pathway such as PI3K or Akt, while potentially desirable, is currently less feasible for patients with PHTS because the results of early phase clinical trials with these inhibitors in cancer patients have not been published. In addition, it is not clear if inhibitors or PI3K or Akt will be as tolerable as inhibitors of mTOR. Inhibitors of mTOR are the most clinically developed, and may serve as viable agents to treat PHTS. Rapamycin, a specific mTOR inhibitor, is FDA approved to prevent transplant rejection and for use in drug-eluting cardiac stents. Temsirolimus, a rapamycin analog, was recently FDA approved for the treatment of advanced renal cell carcinoma. mTOR inhibitors are promising therapies for PHTS patients because loss of PTEN is a positive predictive factor for response to these drugs. 67 These outcomes lend further support for the rationale to treat patients with germline PTEN mutations with rapamycin, as well as the theory that benign tumors in a subset of PS patients are driven by the loss of PTEN, leading to mTOR activation. Finally, the use of rapamycin is also being studied in neurofibromatosis and Birt-Hogg -Dubé, other disorders in which the loss of different tumor suppressor genes alters signaling pathways that converge to activate mTOR.
Considerations for the use of PI3K/Akt/mTOR inhibitors in PHTS As it is possible that PHTS patients could benefit from drugs that inhibit the PI3K/Akt/mTOR pathway, this benefit might not be without cost. The risk/benefit ratio may differ for patients with established malignancy versus patients without malignancy, in that toxicities of pathway inhibitors will be more acceptable for patients with lifethreatening, advanced malignancies. Still, the risk could be high for all PHTS patients. The PI3K/Akt/mTOR pathway has a vital function in many normal cellular processes, including endothelial and cardiomyocyte survival, as well as glucose regulation. 68, 69 Because patients with PHTS bear germline PTEN mutations in every cell, pathway inhibitors could have greater toxicity than that observed in cancer patients whose PTEN mutations are limited to only tumor tissues. This concern may be hypothetical as excess toxicity was not observed in the Bissler et al 66 trial of rapamycin in
TSC. An additional argument against using inhibitors of the PI3K/Akt/mTOR pathway in patients with PHTS is that even if these drugs were to compensate for loss of PTEN lipid phosphatase activity, they would not compensate for other functions of PTEN such as protein phosphatase activity and maintenance of chromosomal stability. Two other considerations apply specifically to mTOR inhibitors. First, the use of mTOR inhibitors can lead to feedback activation of Akt, which could negate any effect of mTOR inhibitors by promoting propagation of the Akt signal to other downstream substrates. 70 -72 This phenomenon was recently demonstrated in a trial of rapamycin in patients with PTEN-deficient glioblastoma, in which feedback activation of Akt was associated with a shorter time to disease progression. 73 However, it is unclear how widely such feedback will be observed.
Another concern with rapamycin is that it has a 'black-box' warning regarding the possibility of developing opportunistic infections and lymphomas in the setting of immune suppression. However, the attribution of this risk is based on organ transplant patients receiving rapamycin in combination with cyclosporine and/or corticosteroids. It has yet to be determined whether single-agent therapy with rapamycin or its analogs would produce the same effects on immune function. Reassuringly, no episodes of opportunistic infection were reported in the study of rapamycin in patients with TSC. 66 
Future directions for PHTS
The future for PHTS patients has great promise because of efforts to improve diagnostic criteria, and the development of new therapeutics that will present challenges to traditional thinking about clinical trial design. Distinctions between the various PHTS syndromes, especially between CS and BRRS, may no longer be clinically relevant. In light of this, an international collaborative effort is underway to prospectively collect genotypic and phenotypic data from thousands of CS patients to identify the simplest means by which to predict germline PTEN mutation. 35 This analysis may simplify the diagnostic criteria and ultimately group BRRS and CS into one syndrome. Revised diagnostic criteria may also decrease the complexity associated with diagnosing PHTS and ensure that patients with PTEN mutations are better recognized by the medical community so that genotyping can be performed and appropriate cancer surveillance utilized. As the understanding of the spectrum of disorders associated with PTEN germline mutation expands, so too will the understanding of PTEN biology. Potential therapies for PHTS that are currently available for clinical testing include rapamycin and its analogs that are highly specific for mTOR, but indirectly inhibit mTOR by binding FKBP12. Newer, direct mTOR inhibitors that target the ATP-binding domain are also being developed. 74, 75 These inhibitors will likely have different properties than rapamycin or its analogs. For example, the similarity of structure of the ATP-binding domains in kinases related to mTOR suggests that direct mTOR inhibitors might also inhibit kinases such as class I PI3K isoforms, and DNA repair enzymes such as DNA-PK and ATM. This has the potential advantage of negating feedback Akt activation that might be observed with agents that only inhibit mTOR inhibition. However, such activity may also be associated with greater toxicity than rapamycin, and thus mTOR inhibitors with a wide spectrum of activity should be initially tested only in PHTS patients with advanced malignancy, where the potential benefits may outweigh the risks. In addition to utilizing inhibitors of the PI3K/Akt/mTOR pathway, future therapies for PHTS may use alternative strategies to restore PTEN function. For example, it might be possible to counteract mutations in PTEN outside the phosphatase domain that lead to increased protein degradation by using a proteosome inhibitor such as bortezomib. Blocking the proteosome would decrease degradation and could increase PTEN protein levels. In patients whose PTEN mutations are outside of exon 5, PTEN phosphatase function might be restored by this approach. In addition, it is possible that gene targets of PTEN outside the canonical PI3K/Akt/mTOR pathway could also be exploited. Such targets could include PINK1, a PTEN-induced protein kinase. Although agonists of PINK1 may prove to be a viable future strategy for treatment of PHTS, none currently exist. In addition, PINK1 has been studied most extensively in Parkinson disease, 76 and further studies on the function of PINK1 in PHTS and in cancer 77 are needed.
The development of new therapeutics for PHTS will present challenges for clinical trial design. What is the ideal clinical setting in which to test pathway inhibitors in PHTS patients? A traditional drug-development approach would test molecularly targeted agents exclusively in PHTS patients with advanced incurable malignancies who have progressed after receiving 'standard' chemotherapies or are resistant to standard therapies. There are at least two reasons that testing of these agents should be considered earlier in the disease process, especially for patients who only serve to gain marginal benefit from frontline chemotherapy. First, tumors that develop after PTEN loss may be 'addicted' to the subsequent activation of the PI3K/ Akt/mTOR pathway. Previous examples of 'oncogene addiction' such as bcr-abl in chronic myelogenous leukemia, c-kit in GI stromal tumors, and EGFR in lung cancer strongly suggest that drugs that target these 'addictions' are useful as first-line therapies. It is possible that inhibitors of the PI3K/Akt/mTOR pathway might achieve the same success in tumors from PHTS patients driven by the loss of PTEN. Second, PHTS patients suffer significant morbidity from numerous diagnostic work-ups of tumors that form, and significant anxiety from the knowledge of being at increased risk to develop certain cancers. An effective preventive approach could mitigate both of these burdens. Therefore, drugs that have favorable toxicity profiles should be tested in small, short pilot trials with PHTS patients, even if they do not have cancer. Such trials could provide preliminary evidence of pathway inhibition, tolerability, and inhibition of tumor growth. Positive early trials could then be followed by larger trials to assess longterm effects on toxicity and efficacy. Although preventing cancer is a very difficult benchmark to achieve, PHTS patients are unusual in that their predisposition to cancer is based on a defined molecular change, not environmental exposure or behavior. Adopting different concepts of clinical trial design could identify new drugs for the treatment or prevention of tumors related to germline loss of PTEN, and thereby provide hope to patients with PHTS.
